Show simple item record

dc.contributor.authorHernandez-Sanmiguel, Esther 
dc.contributor.authorGargini, Ricardo 
dc.contributor.authorCejalvo, Teresa 
dc.contributor.authorSegura-Collar, Berta 
dc.contributor.authorNuñez-Hervada, Paula 
dc.contributor.authorHortigüela, Rafael 
dc.contributor.authorSepúlveda-Sánchez, Juan Manuel
dc.contributor.authorHernández-Laín, Aurelio
dc.contributor.authorPérez-Núñez, Angel
dc.contributor.authorSanz, Eduardo
dc.contributor.authorSánchez-Gómez, Pilar 
dc.date.accessioned2020-03-02T09:54:32Z
dc.date.available2020-03-02T09:54:32Z
dc.date.issued2019
dc.identifier.citationOxid Med Cell Longev. 2019 Aug 5;2019:9719730.es_ES
dc.identifier.issn1942-0900es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9163
dc.description.abstractGlioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been linked to their therapy resistance. Molecular and cellular components of the tumor microenvironment also play a fundamental role in the aggressiveness of these tumors. In particular, high levels of hypoxia and reactive oxygen species participate in several aspects of GBM biology. Moreover, GBM contains a large number of macrophages, which normally behave as immunosuppressive tumor-supportive cells. In fact, the presence of both, hypoxia and M2-like macrophages, correlates with malignancy and poor prognosis in gliomas. Antioxidant agents, as nutritional supplements, might have antitumor activity. Ocoxin® oral solution (OOS), in particular, has anti-inflammatory and antioxidant properties, as well as antitumor properties in several neoplasia, without known side effects. Here, we describe how OOS affects stem cell properties in certain GBMs, slowing down their tumor growth. In parallel, OOS has a direct effect on macrophage polarization in vitro and in vivo, inhibiting the protumoral features of M2 macrophages. Therefore, OOS could be a feasible candidate to be used in combination therapies during GBM treatment because it can target the highly resilient CSCs as well as their supportive immune microenvironment, without adding toxicity to conventional treatments.es_ES
dc.description.sponsorshipThe authors would like to acknowledge Atanasio Pandiella for critical comments on the manuscript, Rosella Galli for donating GBM1, and Jacqueline Gutiérrez, Daniela Moiseev, Daniel Batzan, and Mario Alia for their technical support. RG has been funded by the Fundación Científica Asociación Española Contra el Cáncer. Research has been funded by grants from Fundación Científica Asociación Española Contra el Cáncer (18/006) to JMS; from MINECO: Acción Estratégica en Salud (AES) PI13/01258 to AHL; AES PI17/01621 to JMS; Red Temática de Investigación Cooperativa en Cancer (RTICC) RD12/0036/0027 to AHL, JMS, APN, and PSG; and MINECO-RETOS/FEDER SAF2015-65175 to PSG.es_ES
dc.language.isoenges_ES
dc.publisherHindawi es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshAscorbic Acid es_ES
dc.subject.meshGlioblastoma es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMacrophages es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Nude es_ES
dc.subject.meshNeoplastic Stem Cells es_ES
dc.subject.meshPlant Extracts es_ES
dc.subject.meshVitamin B 12 es_ES
dc.subject.meshVitamin B 6 es_ES
dc.titleOcoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastomaes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID31467641es_ES
dc.format.volume2019es_ES
dc.format.page9719730es_ES
dc.identifier.doi10.1155/2019/9719730es_ES
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderRed Temática de Investigación Cooperativa en Cáncer (RTICC) (España) 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1942-0994es_ES
dc.relation.publisherversionhttps://doi.org/10.1155/2019/9719730es_ES
dc.identifier.journalOxidative medicine and cellular longevityes_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI18/006es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/01621es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/01258es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0036/0027es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2015-65175es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional